Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Laboratories reported impressive growth in its Continuous Glucose Monitoring (CGM) segment, with sales reaching approximately $2.0 billion and exhibiting a year-over-year increase of 12.2%, contributing to a total of over $7.5 billion in CGM sales for 2025, up 17% year-over-year. Additionally, the company expanded its profit margins in 2025, adding 50 basis points to gross margins and 100 basis points to EBIT year-over-year, highlighting strong operational efficiencies despite some quarterly sales weakness. Abbott's commitment to shareholder returns is evidenced by its consistent dividend growth for over 50 consecutive years, underpinning the company's stability and long-term financial health.

Abbott Laboratories reported disappointing Q4 results, with organic sales growth of only 3.8% year-over-year, indicating a notable slowdown across its Nutrition and Diagnostics divisions, ultimately leading to an overall top-line miss. The company's earnings per share (EPS) guidance of $1.12-$1.18 fell short of market expectations, with substantial underperformance noted in nearly all segments, particularly within the Devices business and a reduction in sales projections for 2026. Additional challenges, including declining Covid-19 testing revenue, macroeconomic pressures such as inflation and foreign exchange fluctuations, further exacerbated the company’s weakened financial outlook.